Could a smartphone app ease the breast cancer journey?

NCT ID NCT07696637

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests an app called Access My Breast Cancer Care, designed to help breast cancer patients manage their treatment journey. The app includes educational resources, a calendar, symptom tracker, and a community forum. Researchers will compare app users to those receiving standard care, measuring satisfaction, emergency visits, and wait times. The study involves 148 adults with breast cancer or a BRCA mutation who are having breast reconstruction surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Access My Breast Cancer Care App
What this could lead to
If effective, this app could help breast cancer patients feel more in control, reduce emergency visits, and improve satisfaction with their care.
What could go wrong
This is a small trial testing a digital tool, not a medical treatment. The app may not reduce complications or improve outcomes for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Providence Health Care

    RECRUITING

    Vancouver, British Columbia, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vancouver Coastal Health

    RECRUITING

    Vancouver, British Columbia, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.